LEXINGTON, Mass.--(BUSINESS WIRE)--May 11, 2006--Predix Pharmaceuticals Holdings, Inc., which recently announced a definitive agreement to merge with EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX - News), announced today that the Journal of Medicinal Chemistry, the official peer-reviewed journal of the American Chemical Society, has published a paper describing the novel discovery process of Predix's lead drug candidate for generalized anxiety disorder, PRX-00023, in the May 9, 2006 web-release issue of the Journal (Volume 49). The publication reports on the discovery of a potent, highly selective, long acting, non-azapirone 5-HT1A agonist in development for the treatment of anxiety and depression. PRX-00023 is now in a Phase III clinical trial for generalized anxiety disorder (GAD).
